Sapiens International Q3 Adjusted Earnings Down, Revenue Rises-March 2024-www.financetom.com

Sapiens International Q3 Adjusted Earnings Down, Revenue Rises

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sapiens International Q3 Adjusted Earnings Down, Revenue Rises

Nov 13, 2025 3:36 AM

06:06 AM EST, 11/13/2025 (MT Newswires) -- Sapiens International ( SPNS ) reported Q3 adjusted earnings Thursday of $0.36 per diluted share, down from $0.37 a year earlier.

Three analysts polled by FactSet expected $0.35.

Revenue for the quarter ended Sept. 30 was $152.3 million, up from $137 million a year earlier.

Three analysts surveyed by FactSet expected $148.2 million.

Previous page： Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says Next page： Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says

Mar 24, 2026

March 24 (Reuters) - Ford Motor ( F ) is recalling 254,640 vehicles in the U.S. over issues that may result in the loss of rearview camera image and some advanced driver assistance features, the U.S. National Highway Traffic Safety Administration said on Tuesday. ...

Ford to recall over 254,600 U.S. vehicles over issues with assistance features, NHTSA says

Mar 24, 2026

Regeneron, Sanofi's Dupixent Approved in Japan as Bullous Pemphigoid Treatment

Mar 24, 2026

03:13 AM EDT, 03/24/2026 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Tuesday the Ministry of Health, Labor and Welfare in Japan approved Dupixent, or dupilumab, as treatment for moderate-to-severe bullous pemphigoid, a rare skin disease. The approval was based on data from a phase 2/3 trial that showed over four times more patients...

Vertiv to Buy ThermoKey for Undisclosed Sum

Mar 24, 2026

03:17 AM EDT, 03/24/2026 (MT Newswires) -- Vertiv Holdings ( VRT ) said late Monday it agreed to acquire ThermoKey, a provider of heat rejection and heat-exchange technologies based in Italy. The deal is expected to expand the company's thermal management portfolio and manufacturing capabilities, Vertiv ( VRT ) said. Financial terms were not disclosed. Closing of the deal is...